Clinical Studies

Ethos Precision Medicine Umbrella Study for Hemangiosarcoma (ePUSH)

CURRENTLY ENROLLING

Hemangiosarcoma (HAS) is a highly aggressive cancer affecting dogs, often leading to sudden and severe health crises. This study aims to find new treatments for hemangiosarcoma, offering hope for improved outcomes and reducing unnecessary euthanasia for splenic tumors.

ELIGIBILITY CRITERIA:

• Any dog diagnosed with a ruptured splenic tumor whose owners are pursuing surgery for splenectomy.
• No evidence of metastasis as determined via chest x-rays and during surgery.
• Dogs weighing more than 5kg and less than 45kg

The Objective of This Study: The Ethos-PUSH study is investigating the use of novel drugs for the treatment of hemangiosarcoma (HSA) with the goal of curing this aggressive cancer in dogs.

What We’ve Learned: We have learned that many splenic tumors are benign (40-50%) and patients can be cured with surgery alone.

The Study Process: Eligible patients will have various blood, tissue, and fecal samples collected at the time of splenectomy surgery. Patients found to have HSA following surgery will be eligible to continue on to the second phase of the trial and will receive cutting-edge therapies at no cost to the pet owner.

Pet Owner Resources: Click the links below for more information about eligibility, steps, timelines, and treatments associated with this study.

• Study Guide: Hemoabdomen – ETHOS-PUSH Phase 1
• Study Guide: Hemangiosarcoma – ETHOS-PUSH Phase 2

If your dog has been diagnosed with hemangiosarcoma, you may be eligible to participate in this trial. If you are interested, please fill out the form below. Our expert team of veterinarians will be in touch to confirm eligibility and discuss next steps.

Interested?

Enroll or request more information below.